Date: 26-27 March 2025

Location: Strasbourg, France

Working language: English

Human plasma is the only resource to produce plasma-derived medicinal products (PDMPs) which are critical for the treatment of patients with life-threatening diseases, including bleeding disorders, immune system disorders and several other severe pathologies.

The last two decades the demand for plasma for the production of PDMP has considerably increased and this trend continues to grow. Due to an imbalance in the global collection of plasma needed for PDMP production, Europe is highly dependent on plasma imports from the USA.

With a view to increasing European self-sufficiency, recent and ongoing European initiatives, developments in member states and a changing regulatory landscape in the European Union (EU), have sought to support strengthening the supply of plasma and PDMP in Europe.

This event will provide an update on the latest developments in plasma supply in Europe and give participants an opportunity to exchange on strategies to improve and increase the safe collection and adequate supply of plasma and plasma-derived medicinal products (PDMP), addressing current challenges, key needs and actions.

As part of a continuous effort to build upon recent and ongoing initiatives aimed at increasing and improving plasma collection and PDMP supply in European countries, and in the context of the changing regulatory landscape in the EU, this event will cover the entire plasma-to-PDMP-to-patient chain. Topics include:

• Donor protection;
• Blood and plasma collection;
• Plasma fractionation;
• PDMP - supply, demand and use.

PDMP alternatives will also be considered.

This IN-PERSON event will take place on 26-27 March 2025.

Download the programme (available soon).

This event is ideal for professionals working in blood and plasma collection, PDMP manufacturing, patient and donor associations, blood and pharmaceutical regulation.

This event is an IN-PERSON ONLY. Registration is free of charge.

Register here

The event is organised by the European Directorate for the Quality of Medicines & HealthCare (EDQM), under the aegis of the European Committee on Blood Transfusion (CD-P-TS), with funding by the EDQM of the Council of Europe and the European Commission (EC).